All In Biotech

Drug Trial Radar · NCT04371874

The Standardized Management of Hypertension in Rural Shaanxi

The Standardized and Economical Mode for the Prevention and Management of Chronic Cardiovascular Diseases: Matrix System From Rural Shaanxi ( MATRIX ) Ⅰ

Last checked: Nov 19, 2026Latest source record: May 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,210

Actual

Start

Jan 2014

Primary completion

Jul 2017

Study completion Feb 2019

Sponsor

Lead sponsor
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to build a prevention and management system of hypertension in rural Shaanxi, China, which tries to use the standardized and economical methods to improve the outcome of chronic cardiovascular diseases.

Conditions

  • Hypertension

Interventions

  • Hydrochlorothiazide, Captopril, Nitrendipine, AspirinDrug

    The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the improvement of control rate of hypertension with low-cost in rural ShaanxiTime frame: Patients in the TDP group accepted protocol of TDP to manage hypertension and patients in the control group were managed by the original protocol for six months. Compare the change of control rate at baseline and the end of the sixth month.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the first affiliated hospital of Xi'an Jiaotong university

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.